WFIA

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, April 1, 2024
Research, ADHD, Psych, NDA, Sale, Cingulata, Attention deficit hyperactivity disorder, Insurance, IND, Market, Adolescence, Safety, Clutch (eggs), Poster, WFIA, FDA, Security (finance)

KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update. Highlights include capital raised from multiple sources and the addition of three independent board members.

Key Points: 
  • “Our lead asset CTx-1301 continues to impress clinical investigators and key opinion leaders as we share our Phase 3 results.
  • These tailwinds put Cingulate in a position to obtain non-dilutive capital and expand our pipeline of assets.
  • Looking ahead, Cingulate has several financial instruments in place to raise additional capital while fighting to preserve shareholder’s equity.
  • “Overall, I am very pleased with the progress made by our team in 2023 and into 2024.

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Retrieved on: 
Monday, January 29, 2024
WFIA, CTX, Cingulata, Regulation D, Sale, Act, Security (finance)

The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024 was $4.35 per share.

Key Points: 
  • The closing price of Cingulate’s common stock on Nasdaq on January 24, 2024 was $4.35 per share.
  • Cingulate, Cingulate Therapeutics LLC (CTx) and WFIA entered into a Note Conversion Agreement on January 25, 2024, pursuant to which WFIA agreed to convert the remaining $3.0 million of principal under its outstanding note, plus all accrued interest thereon, or $3.3 million total, into pre-funded warrants (“the Pre-Funded Warrants”) to purchase 687,043 shares of Cingulate’s common stock.
  • The Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.0001 per share, subject to a beneficial ownership blocker of 19.99%.
  • Following the conversion, all debt and accrued interest with WFIA is paid in full.

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, November 13, 2023
WFIA, Safety, Exercise, Psych, Patient, ADHD, Series, Cingulata, Dietary supplement, Security (finance), Adult, AISRS

KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the quarter ended September 30, 2023, as well as a clinical and business update.

Key Points: 
  • If results from this study are successful, pivotal Phase 3 clinical trials in all patient segments for CTx-1302 are expected to begin in 2025.
  • Cash Position: As of September 30, 2023, Cingulate had $2.0 million in cash and cash equivalents.
  • Cingulate expects its cash and cash equivalents will enable the Company to fund its research and development and operating expenditures through mid-November 2023.
  • Net loss was $16.6 million for the nine months ended September 30, 2023, compared to $13.0 million for the same period in 2022.

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Retrieved on: 
Friday, September 8, 2023
Cingulata, Act, WFIA, Regulation D, Sale, CTX, Precision Time Protocol, Security (finance)

The closing price of Cingulate’s common stock on Nasdaq on September 8, 2023 was $0.5776 per share.

Key Points: 
  • The closing price of Cingulate’s common stock on Nasdaq on September 8, 2023 was $0.5776 per share.
  • The debt conversion follows WFIA’s purchase of $1.0 million of Cingulate common stock in a private placement transaction in August 2023.
  • The Pre-Funded Warrants have no expiration date and are exercisable immediately at an exercise price of $0.0001 per share, subject to a beneficial ownership blocker of 19.99%.
  • Following the conversion, $3.0 million in principal plus $0.1 million in accrued interest remained outstanding under the WFIA note which matures in August 2025.

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Monday, August 14, 2023
Insurance, Cingulata, Research and development, Doctor of Pharmacy, Anxiety, Dextroamphetamine, Policy, New Drug Application, ADHD, NDA, WFIA, G&A, Research, Meta-analysis, Faraone, Federal Food, Drug, and Cosmetic Act, Market, Buspirone, Patient, Administration, Associate, Adolescence, R, FDA, IND, Precision Time Protocol Industry Profile, Safety, Dietary supplement, Pharmaceutical industry, Rare-earth element, Cryptocurrency

KANSAS CITY, Kan., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate or the Company), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the quarter ended June 30, 2023, as well as a clinical and business update. Among other highlights, the Company announced a $1 million dollar investment from Werth Family Investment Associates LLC (WFIA), top-line results following the completion of a Phase 3 Adult Efficacy and Safety Trial of CTx-1301, and the initiation of the CTx-1301 Phase 3 pediatric and adolescent studies.

Key Points: 
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the streamlined approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • As part of that effort:
    Cingulate completed a Phase 3 adult dose-optimization study in June 2023 and announced top-line results in July 2023.
  • Assuming positive clinical results from the upcoming Phase 3 trials, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in the second half of 2024 under the Section 505(b)(2) pathway.
  • Cingulate expects its cash and cash equivalents will enable the Company to fund its research and development and operating expenditures into September 2023.

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

Retrieved on: 
Wednesday, May 10, 2023
Insurance, Research and development, Food, Anxiety, Dextroamphetamine, Overalls, Policy, Calendar, ADHD, NDA, WFIA, G&A, Research, Lincoln Park, Federal Food, Drug, and Cosmetic Act, Buspirone, ATM, CDMO, Attention deficit hyperactivity disorder predominantly inattentive, Patient, Administration, Associate, Adolescence, R, FDA, PTR, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Market, Precision Time Protocol Industry Profile, Safety, Fine chemical, Cryptocurrency, Pharmaceutical industry, Cingulata, Society, Indegene, Wainwright

KANSAS CITY, Kan., May 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update. Among other highlights, the Company announced it has obtained an additional $3 million of debt financing, successfully completed the transfer of its proprietary PTR™ manufacturing processes to Societal CDMO, Inc. (Societal) and entered into a joint commercialization agreement with Indegene to provide commercial support for CTx-1301 upon approval from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • CTx-1301: Cingulate advanced its clinical program for CTx-1301 on the streamlined approval pathway under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
  • Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit the NDA for CTx-1301 in mid-2024 under the Section 505(b)(2) pathway.
  • Cash Position: As of March 31, 2023, Cingulate had $1.7 million in cash and cash equivalents.
  • This decrease in manufacturing expense was slightly offset by an increase in clinical and regulatory costs as we initiated a Phase 3 clinical trial for CTx-1301 in the first quarter of 2023.

The World Film Industry Association was inaugurated in Los Angeles and Hai-ge Wang was elected as the president

Retrieved on: 
Friday, December 30, 2022
Film & Motion Pictures, Entertainment, Loews Hotels, COVID-19, Multimedia, California State Assembly, Speech, Representative, Industrialisation, Conference, WFIA, Film

Recently, the World Film Industry Association, was inaugurated at the LOEWS Hotel in Los Angeles.

Key Points: 
  • Recently, the World Film Industry Association, was inaugurated at the LOEWS Hotel in Los Angeles.
  • Hai-ge Wang, an internationally renowned curator, producer and outstanding leader in the film industry, was elected as the first president.
  • At a time when the world film industry is at a critical turning point, global cultural filed and government leaders need to work together to develop long-term policies and strategies to revitalize the hard-hit global film industry.
  • As the world's first offline conference-based international film organisation this year, the establishment of the World Film Industry Association has attracted widespread attention with over 300 total registered participants.